menu
    • menu
    [{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"EC-18","moa":"","graph1":"Pharmacology\/Toxicology","graph2":"Undisclosed","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"","sponsorNew":"Enzychem Lifesciences Corporation \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Enzychem Lifesciences Corporation \/ National Institutes of Health"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CMC Pharmaceuticals

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            CMC Pharmaceuticals

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atropine Sulfate

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Undisclosed

                            Sponsor : U.S. Defense Department

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            CMC Pharmaceuticals Awarded SBIR Grant for Concentrated Atropine Formulation

                            Details : The Phase I SBIR award will fund the formulation and analytical development of a concentrated Atropine Sulfate Drug Product with the aim to aid the military in treating organophosphate poisoning in service members.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 06, 2022

                            Lead Product(s) : Atropine Sulfate

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Undisclosed

                            Sponsor : U.S. Defense Department

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Enzychem Lifesciences Corporation

                            South Korea arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Enzychem Lifesciences Corporation

                            South Korea arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EC-18

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Undisclosed

                            Sponsor : National Institutes of Health

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Enzychem Lifesciences Selected to Collaborate with NIAID CCRP on the CERF Program

                            Details : Enzychem's lead compound, EC-18, is an immunomodulator that rapidly resolves inflammation and restores immune homeostasis by accelerating the intracellular trafficking of pattern recognition receptor-bound pathogenic invaders or endogenous danger signals...

                            Brand Name : EC-18

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 20, 2021

                            Lead Product(s) : EC-18

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Undisclosed

                            Sponsor : National Institutes of Health

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Eton Pharmaceuticals

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Eton Pharmaceuticals

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ethanol

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Eton Pharmaceuticals Submits New Drug Application to the FDA for Orphan Drug Dehydrated Alcohol Injection (DS-...

                            Details : Eton Pharmaceuticals has submitted a new drug application (NDA) for dehydrated alcohol injection, previously known as the company’s DS-100 product candidate, to the U.S. Food & Drug Administration (FDA) for the treatment of methanol poisoning.

                            Brand Name : DS-100

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 27, 2020

                            Lead Product(s) : Ethanol

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth